Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,713
  • Shares Outstanding, K 52,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,450 K
  • 36-Month Beta 2.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/18
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.17 +35.04%
on 08/03/18
1.64 -3.66%
on 08/15/18
+0.28 (+21.54%)
since 07/13/18
3-Month
1.17 +35.04%
on 08/03/18
1.80 -12.22%
on 05/16/18
-0.13 (-7.60%)
since 05/15/18
52-Week
0.88 +79.55%
on 08/23/17
2.95 -46.44%
on 11/13/17
+0.66 (+71.74%)
since 08/15/17

Most Recent Stories

More News
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)"), today announced the appointment of Punit Dhillon, former President & CEO...

NMUS : 0.1900 (unch)
ONCS : 1.58 (unch)
EMH.VN : 2.820 (+8.05%)
ARTH : 0.3700 (unch)
OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer, presented...

ONCS : 1.58 (unch)
Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks

Stock Research Monitor: ONCS, SGEN, and SLS

ONCS : 1.58 (unch)
SGEN : 73.90 (-0.98%)
OncoSec Provides Outlook for Second Half of 2018

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, provided an update of key value-creating milestones for the second half of 2018 and a review...

ONCS : 1.58 (unch)
OncoSec Added to the Russell Microcap® Index

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today that it has been added to the Russell Microcap® Index, effective Friday,...

ONCS : 1.58 (unch)
Factors of Influence in 2018, Key Indicators and Opportunity within PPL, The Travelers Companies, Xilinx, United Bankshares, DaVita, and OncoSec Medical -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PPL Corporation (NYSE:PPL),...

UBSI : 38.45 (-1.54%)
XLNX : 70.61 (-0.77%)
TRV : 128.77 (+0.96%)
ONCS : 1.58 (unch)
PPL : 29.20 (-0.24%)
DVA : 71.89 (-0.40%)
OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the presentation of a Trials in Progress poster at the American Society of...

ONCS : 1.58 (unch)
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck (known as MSD...

ONCS : 1.58 (unch)
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec Medical

If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD), Marinus...

ONCS : 1.58 (unch)
MRTX : 58.25 (-0.17%)
MNKD : 1.11 (-1.77%)
MRNS : 5.49 (-5.83%)
OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, Chief Executive Officer of OncoSec, will present...

ONCS : 1.58 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 1.71
1st Resistance Point 1.65
Last Price 1.58
1st Support Level 1.51
2nd Support Level 1.43

See More

52-Week High 2.95
Fibonacci 61.8% 2.16
Fibonacci 50% 1.91
Fibonacci 38.2% 1.67
Last Price 1.58
52-Week Low 0.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar